Zydus Cadila has launched Lipaglyn, a novel drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia and Hypertriglyeeridemia in Type II diabetes, not controlled by statins alone. Lipaglyn will be available across India and can be prescribed by cardiologists, dialectologists and general physicians. The therapy is priced at Rs 2.5.90 per tablet. The therapy is marketed by Zydus Discovery, a new division launched to exclusively market the original research products of the group's research pipeline, the first being Lipaglyn. With strength of 200 people, the division also has regional medical advisors to support the scientific promotion or discovery research products.

Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

971.15 -2.75 (-0.28%)
23-Dec-2024 14:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1817.50
Dr. Reddys Lab 1336.30
Cipla 1474.25
Lupin 2159.70
Zydus Lifesciences 971.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.